Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from the completed first part of its Phase 2/3 clinical trial assessing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE